Patients with rare epithelial growth factor receptor (EGFR) mutations have limited treatment options and often face a poor prognosis due to the reduced efficacy of tyrosine kinase inhibitors (TKIs), which are the standard treatment for Non-small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.